A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Overview of attention for article published in Clinical Cancer Research, September 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

blogs: 1 blog

twitter: 30 tweeters

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 4 Mendeley

Summary Blogs Twitter Dimensions citations

So far, Altmetric has seen 1 blog post.

Analyzing the Safety and Efficacy of Lenvatinib Plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Physician's Weekly, 09 Jan 2023

The following is a summary of “A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.